|
Infant Respiratory Distress Syndrome (IRDS)
|
Surfactant Insufficiency
|
[1, 65, 74, 208, 225, 227, 232, 233, 235, 239, 240, 244, 245]
|
|
Acute Respiratory Distress Syndrome (ARDS/RDS)
|
Neutral Lipid Accumulation
|
[51]
|
|
Surfactant Lipid Deficiency
|
[27, 67,68,69, 247, 248]
|
|
Increased PL-Mediated Fibrin Polymerization
|
[247]
|
|
Protective Role of Sphingolipid Signaling
|
[249,250,251]
|
|
Acute Lung Injury (ALI)
|
T2C Damage
|
[134, 252, 253]
|
|
Surfactant Lipid Alterations
|
[134, 242, 252, 253]
|
|
Dysregulated Lipid Transport
|
[177, 178]
|
|
Protective Role of Sphingolipid Signaling
|
[249,250,251]
|
|
Chronic Obstructive Pulmonary Disease (COPD)
|
Surfactant Lipid Deficiency
|
[6, 7, 67, 88,89,90,91, 95, 98,99,100,101,102,103,104]
|
|
Disrupted Reverse Lipid Transport
|
[105, 106]
|
|
T2C Damage
|
[92,93,94,95,96,97,98, 103, 107, 108]
|
|
Disrupted Alveolar Architecture
|
[104]
|
|
Impaired AM Sphingolipid Signaling
|
[110,111,112,113]
|
|
Vaping-Associated Lung Injury
|
Intracellular and Luminal Lipid Accumulation
|
[115,116,117,118,119,120, 194, 195]
|
|
Dysregulated AM Lipid Metabolism
|
[196]
|
|
Idiopathic Pulmonary Fibrosis (IPF)
|
Surfactant Lipid Alterations
|
[67, 129,130,131,132,133,134, 139,140,141, 143,144,145, 148]
|
|
Downregulated T2C Lipid Metabolism
|
[125,126,127,128, 139,140,141, 148, 150]
|
|
T2C ER Stress
|
[147,148,149, 151]
|
|
T2C Damage
|
[135,136,137]
|
|
Dysregulated AM Lipid Metabolism
|
[130, 138, 142]
|
|
Dysregulated Eicosanoid Production
|
[148, 152,153,154,155,156, 158,159,160,161,162,163, 165,166,167,168]
|
|
Dysregulated Sphingolipid Signaling
|
[169,170,171,172,173,174]
|
|
Decreased Alveolar Surface Area
|
[129]
|
|
Pulmonary Alveolar Proteinosis (PAP)
|
Luminal Surfactant Accumulation
|
[6, 63]
|
|
AM Cholesterol Accumulation
|
[59,60,61,62,63,64, 191]
|
|
Pneumonia
|
Surfactant Lipid Alterations
|
[67, 175]
|
|
Dysregulated Lipid Transport
|
[176]
|
|
Host-Pathogen Lipid Interaction
|
[179,180,181,182,183,184,185,186,187,188,189,190]
|
|
Alveolar Cellular Damage
|
[193]
|
|
Influenza
|
Lipid-Mediated Host Defense
|
[5]
|
|
Host-Pathogen Lipid Interaction
|
[205, 206]
|
|
Tuberculosis (TB)
|
Host-Pathogen Lipid Interaction
|
[210, 211, 215,216,217,218]
|
|
Host Eicosanoids Differentially Affect Pathogenesis
|
[212,213,214]
|
|
SARS and SARS-CoV-2
|
Diffuse Alveolar Damage
|
[222, 223]
|
|
T2C Hyperplasia
|
[221, 222]
|
